Martín Igor Gómez-Randulfe, Locum Consultant in Lung and Acute Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Happy to share our new review on evolving treatment for advanced EGFR mutated non small cell lung cancer, now live in Critical Reviews in Oncology and Hematology.
• From single agent osimertinib to combinations with chemotherapy, anti angiogenic agents and the amivantamab plus lazertinib doublet, we map the current first line playbook
• Post progression pathways include antibody drug conjugates and the MARIPOSA-2 regimen
• Emphasis on precision sequencing through dynamic ctDNA tracking and CNS active options to stay ahead of resistance
Thanks to all co-authors: Federico Monaca, Raffaele Califano, David Planchard, Emilio Bria.”
Title: Evolving treatment for advanced Non-small cell lung cancer harbouring common EGFR activating mutations
Journal: Critical Reviews in Oncology/Hematology
Authors: Martín Igor Gómez-Randulfe, Federico Monaca, Raffaele Califano, David Planchard, Emilio Bria
More posts featuring NSCLC on OncoDaily.